Stellar Quarter on the Back of gTamiflu Inventory Build-up; Target Price Raised: Alvogen (Natcos commercialization partner for gTamiflu) launched gTamiflu onDec 12, 2016. But gTamiflu sales to Alvogen were recorded for the quarter ended September 2016, because the agreement is structured such that Natco will sell gTamiflu at cost plus certain markup to Alvogen. The sales are basically inventory build-up of gTamiflu in the run-up to the launch. The profits from gTamiflu sales in US would be shared between Alvogen and Natco.